Compare IDEXX Laboratories, Inc. (IDXX) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Kroger Co — how do they compare? IDEXX Laboratories, Inc. trades at $569.93 (market cap $46.22B), while Kroger Co trades at $56.19 (market cap $34.46B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Kroger Co pays a 2.56% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | KR | |
|---|---|---|
Market Cap | $46.22B | $34.46B |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $75.60 |
52-Week Low | $526.44 | $55.53 |
Enterprise Value | $47.12B | $54.56B |
Dividend Yield | — | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Kroger (KR) trades at $56.15, down 0.58% on the day, reflecting recent market pressure. The stock shows mixed signals with a bearish technical outlook but solid fundamentals including a low P/S ratio of 0.24 and consistent dividend payments. Recent earnings saw a Q1 2026 miss but beats in prior quarters, while analyst consensus remains positive with a $68.25 price target. Cash flow from operations remains strong at $5.79B in 2025, supporting ongoing investments in e-commerce and digital initiatives.
The outlook for KR is cautiously optimistic. Valuation appears reasonable relative to sales, and dividend income provides stability. However, near-term risks include competitive pressures in grocery retail, margin compression from inflation, and technical bearish signals. Investors should weigh strong cash generation against earnings volatility and debt levels that have risen to 30.23% of assets in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
